Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine
Abstract Background Mucopolysaccharidosis (MPS) are a group of lysosomal storage diseases with substantial unmet medical needs—for both patients and caregivers. Approved therapies are limited, and the perception of investigative ones remains enigmatic. Method Using an innovative survey concept based...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-025-03549-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585347414884352 |
|---|---|
| author | Anna-Maria Wiesinger Florian B. Lagler |
| author_facet | Anna-Maria Wiesinger Florian B. Lagler |
| author_sort | Anna-Maria Wiesinger |
| collection | DOAJ |
| description | Abstract Background Mucopolysaccharidosis (MPS) are a group of lysosomal storage diseases with substantial unmet medical needs—for both patients and caregivers. Approved therapies are limited, and the perception of investigative ones remains enigmatic. Method Using an innovative survey concept based on the discrete choice experiment method (DEC) with neuronopathic and non-neuronopathic patient scenarios, we aimed to evaluate how parents of children with MPS perceive different approved and innovative therapies. The questionnaire was distributed via patient organizations in Germany, Switzerland, and Austria. Results Most likely parents would choose an approach to repurposed treatments for their child (neuronopathic: 82%, 14/17 and non-neuronopathic: 94%, 16/17), followed by enzyme replacement therapy (ERT, both 88%, 15/17), hematopoietic stem cell therapy (HSCT, 70%, 12/17 and 76%, 13/17), and finally gene therapy (GT, 58%, 10/17 and 53%, 9/17). The general attitudes strongly influenced decision-making regarding treatment options. While over 80% of respondents who held a positive attitude toward ERT, HSCT, and ITTs indicated they would opt for these therapies in both neuronopathic and non-neuronopathic cases, only about half of the parents with a favorable general view of gene therapy (GT) expressed a positive perception of its likelihood as a treatment option. Furthermore, most parents found mild infections, injection site reactions (ISRs), hypertonia, and treatment-related hospitalizations acceptable and indicated patient organizations as their main source of information. Conclusions This study provides an innovative survey method, thereby offering the rationale for a quantitative risk–benefit model and the importance of patient and caregiver-centered information dissemination, especially for innovative therapies. |
| format | Article |
| id | doaj-art-3f9fc92691984175a839da430bac9f89 |
| institution | Kabale University |
| issn | 1750-1172 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj-art-3f9fc92691984175a839da430bac9f892025-01-26T12:52:20ZengBMCOrphanet Journal of Rare Diseases1750-11722025-01-0120111010.1186/s13023-025-03549-yParental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicineAnna-Maria Wiesinger0Florian B. Lagler1Institute for Inherited Metabolic Disorders, Paracelsus Medical University SalzburgInstitute for Inherited Metabolic Disorders, Paracelsus Medical University SalzburgAbstract Background Mucopolysaccharidosis (MPS) are a group of lysosomal storage diseases with substantial unmet medical needs—for both patients and caregivers. Approved therapies are limited, and the perception of investigative ones remains enigmatic. Method Using an innovative survey concept based on the discrete choice experiment method (DEC) with neuronopathic and non-neuronopathic patient scenarios, we aimed to evaluate how parents of children with MPS perceive different approved and innovative therapies. The questionnaire was distributed via patient organizations in Germany, Switzerland, and Austria. Results Most likely parents would choose an approach to repurposed treatments for their child (neuronopathic: 82%, 14/17 and non-neuronopathic: 94%, 16/17), followed by enzyme replacement therapy (ERT, both 88%, 15/17), hematopoietic stem cell therapy (HSCT, 70%, 12/17 and 76%, 13/17), and finally gene therapy (GT, 58%, 10/17 and 53%, 9/17). The general attitudes strongly influenced decision-making regarding treatment options. While over 80% of respondents who held a positive attitude toward ERT, HSCT, and ITTs indicated they would opt for these therapies in both neuronopathic and non-neuronopathic cases, only about half of the parents with a favorable general view of gene therapy (GT) expressed a positive perception of its likelihood as a treatment option. Furthermore, most parents found mild infections, injection site reactions (ISRs), hypertonia, and treatment-related hospitalizations acceptable and indicated patient organizations as their main source of information. Conclusions This study provides an innovative survey method, thereby offering the rationale for a quantitative risk–benefit model and the importance of patient and caregiver-centered information dissemination, especially for innovative therapies.https://doi.org/10.1186/s13023-025-03549-yMucopolysaccharidosisMPSParental perceptionAttitudesDiscrete choice experimentPersonalized medicine |
| spellingShingle | Anna-Maria Wiesinger Florian B. Lagler Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine Orphanet Journal of Rare Diseases Mucopolysaccharidosis MPS Parental perception Attitudes Discrete choice experiment Personalized medicine |
| title | Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine |
| title_full | Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine |
| title_fullStr | Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine |
| title_full_unstemmed | Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine |
| title_short | Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine |
| title_sort | parental perception of treatment options for mucopolysaccharidosis a survey to bridge the gap for personalized medicine |
| topic | Mucopolysaccharidosis MPS Parental perception Attitudes Discrete choice experiment Personalized medicine |
| url | https://doi.org/10.1186/s13023-025-03549-y |
| work_keys_str_mv | AT annamariawiesinger parentalperceptionoftreatmentoptionsformucopolysaccharidosisasurveytobridgethegapforpersonalizedmedicine AT florianblagler parentalperceptionoftreatmentoptionsformucopolysaccharidosisasurveytobridgethegapforpersonalizedmedicine |